Insulet makes the Omnipod tubeless insulin pump for diabetics.
Insulet Corp. (PODD) is expected to report earnings on Thursday, November 5, 2026, after the close. Estimated release time 07:08 ET. Consensus EPS estimate is $1.59.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | FY2026 Q2 | $1.47 | $1.37 | -6.8% | $801.70M |
| 2026-05-06 | FY2026 Q1 | $1.19 | $1.30 | +9.2% | $761.70M |
| 2026-02-18 | FY2025 Q4 | $1.47 | $1.45 | -1.4% | $783.80M |
| 2025-11-06 | FY2025 Q3 | $1.14 | $1.24 | +8.8% | $706.30M |
| 2025-08-07 | FY2025 Q2 | $0.92 | $1.17 | +27.2% | $649.10M |
| 2025-05-09 | FY2025 Q1 | $0.79 | $1.02 | +29.1% | $569.00M |
| 2025-02-21 | FY2024 Q4 | $1.00 | $1.44 | +44.0% | $597.50M |
| 2024-11-08 | FY2024 Q3 | $0.76 | $1.11 | +46.1% | $543.90M |
PODD has beaten consensus EPS in 6 of its last 8 reported quarters.
Highlights from PODD's Aug 5 report: EPS of $1.37 — a miss vs the $1.47 estimate (-7%); revenue of $802M — in line with the $787M consensus. Focus now shifts to pump adoption and type-2 expansion.
See PODD on the live calendar →